Accelerated arteriosclerosis after transplantation: The possible role of calcium channel blockers

International Journal of Cardiology

Volumn 62, Issue SUPPL. 2, 1997, Pages

  Atkinson, James B ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

Amlodipine; Atherosclerosis; Calcium channel blockers; Transplantation

Indexed keywords

ACETYLCHOLINE; AMLODIPINE; CALCINEURIN; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCERYL TRINITRATE; IMMUNOSUPPRESSIVE AGENT; NIFEDIPINE; PLACEBO; VERAPAMIL;

ANIMAL MODEL; ARTERIOSCLEROSIS; ATHEROGENESIS; CONFERENCE PAPER; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFECT; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; IMMUNE SYSTEM; MAJOR CLINICAL STUDY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; VASCULAR SMOOTH MUSCLE;

AMLODIPINE; ANIMALS; CALCIUM CHANNEL BLOCKERS; CORONARY ARTERIOSCLEROSIS; CORONARY VESSELS; DILTIAZEM; DRUG THERAPY, COMBINATION; HEART TRANSPLANTATION; HUMANS;

EID: 0031593040     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(97)00250-7     Document Type: Conference Paper

References (62)

1. Hosenpud J.D., Novick R.J., Bennett L.E., Keck B.M., Fiol B., Daily O.P. The Registry of the International Society for Heart and Lung Transplantation: Thirteenth official report - 1996. J Heart Lung Transplant. 15:1996;655-674.
2. Gao S.Z., Alderman E.L., Schroeder J.S., Silverman J.F., Hunt S.A. Accelerated coronary vascular disease in the heart transplant patient: coronary arteriographic findings. J Am Coll Cardiol. 12:1988;334-340.
3. Schroeder J.S., Gao S.Z., Hunt S.A., Stinson E.B. Accelerated graft coronary artery disease: diagnosis and prevention. J Heart Lung Transplant. 11:1992;S258-S266.
4. Keogh A.M., Valantine H.A., Hunt S.A.et al. Impact of proximal or midvessel discrete coronary artery stenoses on survival after heart transplantation. J Heart Lung Transplant. 11:1992;892-901.
5. Atkinson JB, Virmani R. Pathology of heart and combined heart-lung transplantation. In: Virmani R, Atkinson JB, Fenoglio JJ, editors. Cardiovascular pathology. Philadelphia: Saunders, 1991:310-333.
6. Mihatsch M.J., Thiel G., Basler V.et al. Morphological patterns in cyclosporine-treated renal transplant recipients. Transplant Proc. 17(suppl 1):1985;101-116.
7. Demetris A.J., Zerbe T., Banner B. Morphology of solid organ allograft arteriopathy: identification of proliferating intimal cell populations. Transplant Proc. 21:1989;3667-3669.
8. Yousem S.A., Paradis I.L., Dauber J.H.et al. Pulmonary arteriosclerosis in long-term human heart-lung transplant recipients. Transplantation. 47:1989;564-569.
9. Arbustini E., Roberts W.C. Morphologic observations in the epicardial coronary arteries and their surroundings late after cardiac transplantation (allograft vascular disease). Am J Cardiol. 78:1996;814-820.
10. Arbustini E., Dal Bello B., Morbini P.et al. Frequency and characteristics of coronary thrombosis in the epicardial coronary arteries after cardiac transplantation. Am J Cardiol. 78:1996;795-800.
11. Atkinson JB. Endomyocardial biopsy of cardiac allografts and transplant atherosclerosis. In: Virmani R, Burke A, Farb A, editors. Atlas of cardiovascular pathology. Philadelphia: Saunders, 1996:24-34.
12. Chomette G., Auriol M., Cabrol C. Chronic rejection in human heart transplantation. J Heart Lung Transplant. 7:1988;292-297.
13. Ardehali A., Drinkwater D.C., Laks H., Drake T.A. Cardiac allograft vasculopathy. Am Heart J. 126:1993;1498-1502.
14. Libby P., Salomon R.N., Payne D.D., Schoen F.J., Pober J.S. Functions of vascular wall cells related to development of transplantation-associated coronary arteriosclerosis. Transplant Proc. 21:1989;3677-3684.
15. Ventura H.O., Mehra M.R., Smart F.W., Stapleton D.D. Cardiac allograft vasculopathy: current concepts. Am Heart J. 129:1995;791-799.
16. Arai S., Okada M., Morimoto T., Hisamochi K., Senoo Y., Teramoto S. The impact of FK506 on graft coronary disease and graft infiltrating lymphocyte subsets following rat heart transplantation comparison with cyclosporin A. J Heart Lung Transplant. 10(Abstract):1991;175.
17. Cramer D.V. Transplant arteriosclerosis. Transplant Sci. 1:1991;60-63.
18. Keogh A., Simons L., Spratt P.et al. Hyperlipidemia after heart transplantation. J Heart Lung Transplant. 7:1988;171-175.
19. Ballantyne C.M., Radovancevic B., Farmer J.A.et al. Hyperlipidemia after heart transplantation: report of a 6-year experience, with treatment recommendations. J Am Coll Cardiol. 19:1992;1315-1321.
20. Escobar A., Ventura H.O., Stapleton D.D.et al. Cardiac allograft vasculopathy assessed by intravascular ultrasonography and nonimmunologic risk factors. Am J Cardiol. 74:1994;1042-1046.
21. Kobashigawa J.A., Katznelson S., Laks H.et al. Effect of pravastatin on outcomes after cardiac transplantation. New Engl J Med. 333:1995;621-627.
22. Mehra M.R., Ventura H.O., Smart F.W.et al. New developments in the diagnosis and management of cardiac allograft vasculopathy. Tex Heart Inst J. 22:1995;138-144.
23. Gao S.Z., Schroeder J.S., Alderman E.L.et al. Clinical and laboratory correlates of accelerated coronary artery disease in the cardiac transplant patient. Circulation. 76(Suppl):1987;V56-V61.
24. Gao S.Z., Schroeder J.S., Hunt S., Stinson E.B. Retransplantation for severe accelerated coronary artery disease in heart transplant recipients. Am J Cardiol. 62:1988;876-881.
25. Waters D., Lesperance J. Calcium channel blockers and coronary atherosclerosis: from the rabbit to the real world. Am Heart J. 128:1994;1309-1316.
26. Atkinson J.B., Wudel J.H., Hoff S.J., Stewart J.R., Frist W.H. Amlodipine reduces graft coronary artery disease in rat heterotopic cardiac allografts. J Heart Lung Transplant. 12:1993;1036-1043.
27. Russell P.S., Chase C.M., Colvin R.B. Accelerated atheromatous lesions in mouse hearts transplanted to apolipoprotein-E-deficient recipients. Am J Pathol. 149:1996;91-99.
28. Nayler W.G., Gu X.H. Protecting the vasculature: an eye toward the future. Am J Cardiol. 66(Suppl):1990;23-27.
29. McMurray H.F., Chahwala S.B. Amlodipine exerts a potent antimigrational effect on aortic smooth muscle cells in culture. J Cardiovasc Pharmacol. 20(Suppl A):1992;S54-S56.
30. Takami H., Backer C.L., Crawford S.E., Pahl E., Mavroudis C. Diltiazem preserves direct vasodilator response but fails to suppress intimal proliferation in rat allograft coronary artery disease. J Heart Lung Transplant. 15:1996;67-77.
31. Fish R.D., Nabel E.G., Selwyn A.P.et al. Responses of coronary arteries of cardiac transplant patients to acetylcholine. J Clin Invest. 81:1988;21-31.
32. Sheehan H., Vetrovec G., Graham S., Mohanty P., Hodgson J.M. Calcium channel antagonists protect against the development of coronary artery disease following cardiac transplant. J Am Coll Cardiol. 17(Abstract):1991;290A.
33. Mehra M.R., Ventura H.O., Smart F.W., Collins T.J., Ramee S.R., Stapleton D.D. An intravascular ultrasound study of the influence of angiotensin-converting enzyme inhibitors and calcium entry blockers on the development of cardiac allograft vasculopathy. Am J Cardiol. 75:1995;853-854.
34. Schroeder J.S., Gao S.Z., Alderman E.L.et al. A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. New Engl J Med. 328:1993;164-170.
35. Schroeder J.S., Gao S.Z. Calcium blockers and atherosclerosis: lessons from the Stanford transplant coronary artery disease/diltiazem trial. Can J Cardiol. 11:1995;710-715.
36. Macdonald P., Keogh A., Marshman D.et al. Two year followup of a prospective randomized study of diltiazem coadministration with cyclosporin after heart transplantation. J Heart Lung Transplant. 12(Abstract):1993;S80.
37. Haworth C, Feldman M. Lymphokines and disease. In: Feldman M, Lamb J, Owen MJ, editors. T-cells. New York: Wiley, 1989:255-279.
38. Habib J.B., Bossaller C., Wells S., Williams C., Morrisett J.D., Henry P.D. Preservation of endothelium-dependent vascular relaxation in cholesterol-fed rabbit by treatment with the calcium blocker PN 200110. Circ Res. 58:1986;305-309.
39. Johnson M.R. Transplant coronary disease: nonimmunologic risk factors. J Heart Lung Transplant. 11(Suppl):1992;S124-S132.
40. Shi C., Lee W.S., He Q.et al. Immunologic basis of transplant-associated arteriosclerosis. Proc Natl Acad Sci USA. 93:1996;4051-4056.
41. Paoletti R., Bernini F., Fumagalli R., Allorio M., Corsini A. Calcium antagonists and low density lipoprotein receptors. Ann New York Acad Sci. 522:1988;390-398.
42. Stein O., Leitersdorf E., Stein Y. Verapamil enhances receptor-mediated endocytosis of low density lipoproteins by aortic cells in culture. Arteriosclerosis. 5:1985;35-44.
43. Orekhov A.N., Tertov V.V., Pivovarova E.M., Sobenin I.A., Akhmedzhanov N.M., Aronov D.M. Effect of amlodipine treatment on atherogenic properties of blood serum and low-density lipoprotein. J Cardiovasc Pharmacol. 26(Suppl A):1995;S25-S33.
44. Daugherty A., Rateri D.L., Schonfeld G., Sobel B.E. Inhibition of cholesteryl ester deposition in macrophages by calcium entry blockers: an effect dissociable from calcium entry blockade. Br J Pharmacol. 91:1987;113-118.
45. Stein O., Halperin G., Stein Y. Long-term effects of verapamil on aortic smooth muscle cells cultured in the presence of hypercholesterolemic serum. Arteriosclerosis. 7:1987;585-592.
46. Etingin O.R., Hajjar D.P. Nifedipine increases cholesteryl ester hydrolytic activity in lipid-laden rabbit arterial smooth muscle cells: a possible mechanism for its antiatherogenic effect. J Clin Invest. 75:1985;1554-1558.
47. Kramsch D.M., Sharma R.C., Hodis H.N. Amlodipine suppresses in vivo low-density lipoprotein oxidation, hyperinsulinemia and atherosclerosis in primates. Circulation. 88(Suppl; Abstract):1993;I562.
48. Kramsch D.M. Atherosclerosis progression/regression: lipoprotein and vessel wall determinants. Atherosclerosis. 118(Suppl):1995;S29-S36.
49. Chitwood K.K., Heim-Duthoy K.L. Immunosuppressive properties of calcium channel blockers. Pharmacotherapy. 13:1993;447-454.
50. Birx D.L., Berger M., Fleisher T.A. The interference of T cell activation by calcium channel blocking agents. J Immunol. 133:1984;2904-2909.
51. Solovera J.J., Alvarez-Mon M., Casas J., Carballido J., Durantez A. Inhibition of human natural killer (NK) activity by calcium channel modulators and a calmodulin antagonist. J Immunol. 139:1987;876-880.
52. Derenne F., Vanhaeverbeek M., Brohee D. Nifedipine-induced hyporeactivity in delayed hypersensitivity skin tests. Int J Immunopharmacol. 9:1987;741-744.
53. Wagner K., Philipp T., Heinemeyer G., Brockmuller F., Roots I., Neumayer H.H. Interaction of cyclosporine and calcium antagonists. Transplant Proc. 21:1989;1453-1456.
54. McMillen M.A., Tesi R.J., Baumgarten W.B., Jaffe B.M., Wait R.B. Potentiation of cyclosporine by verapamil in vitro. Transplantation. 40:1985;444-446.
55. Weir M.R., Peppler R., Gomolka D., Handwerger B.S. Additive inhibition of afferent and efferent immunological responses of human peripheral blood mononuclear cells by verapamil and cyclosporine. Transplantation. 51:1991;851-857.
56. Padberg W.M., Bodewig C., Schafer H., Muhrer K.H., Schwemmie K. Synergistic immunosuppressive effect of low-dose cyclosporine A and the calcium antagonist nifedipine, mediated by the generation of suppressor cells. Transplant Proc. 22:1990;2337.
57. Tesi R.J., Hong J., Butt K.M.H., Jaffe B.M., McMillen M.A. In vivo potentiation of cyclosporine immunosuppression by calcium antagonists. Transplant Proc. 19:1987;1382-1384.
58. Dumont L., Chen H., Daloze P., Xu D., Garceau D. Immunosuppressive properties of the benzothiazepine calcium antagonists diltiazem and clentiazem, with and without cyclosporine, in heterotopic rat heart transplantation. Transplant. 56:1993;181-184.
59. Halloran P.F., Miller L.W. In vivo immunosuppressive mechanisms. J Heart Lung Transplant. 15:1996;959-971.
60. Griffith J.P., Kim J.L., Kim E.E.et al. X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex. Cell. 82:1995;507-522.
61. Kissinger C.R., Parge H.E., Knighton D.R.et al. Crystal structure of human calcineurin and the human FKBP12-FK506-calcineurin complex. Nature. 378:1995;641-644.
62. Rao A. NF-ATp: a transcription factor required for the co-ordinate induction of several cytokine genes. Immunol Today. 15:1994;274-280.